Literature DB >> 20527993

A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization.

Marisa K Joubert1, Nichole Kinsley, Alexio Capovilla, B Trevor Sewell, Mohamed A Jaffer, Makobetsa Khati.   

Abstract

The HIV-1 envelope glycoprotein, gp120, is a key target for a class of drugs called entry inhibitors. Here we used molecular modeling to construct a three-dimensional model of an anti-gp120 RNA aptamer, B40t77, alone and in complex with gp120. An initial model of B40t77 was built from the predicted secondary structure and then subjected to a combination of energy minimization and molecular dynamics. To model the B40t77-gp120 complex, we docked the B40t77 predicted structure onto the CD4-induced epitope of the gp120 crystal structure. A series of gp120 point mutations in the predicted B40t77-gp120 interface were measured for their binding affinity for B40t77 by surface plasmon resonance. According to the model, of the 10 gp120 amino acids that showed a reduction in the level of binding when mutated to alanine, all of them are modeled as making direct contact with B40t77 as part of a hydrogen bonding network. Comparison by electron microscopy of the B40t77-gp120 complex with gp120 alone revealed that only the longest dimension of the complex significantly increased in length, in a manner consistent with the predicted model. Binding assays revealed that B40t77 can weaken the binding of gp120 to the monoclonal antibodies B6, B12, and 2G12, none of which have binding sites that overlap with B40t77, as well as strengthen the binding to the antibody 19b. Thus, B40t77 may induce distant conformational changes in gp120 that disrupt its association with host cells and may suggest a mechanism for aptamer neutralization of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527993     DOI: 10.1021/bi100301k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Authors:  Michael D Moore; Jonathan Cookson; Veronica K Coventry; Brian Sproat; Lorna Rabe; Ross D Cranston; Ian McGowan; William James
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

3.  HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer.

Authors:  Walter R Lopes de Campos; Nthato Chirwa; Grace London; Lia S Rotherham; Lynn Morris; Bongani M Mayosi; Makobetsa Khati
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

4.  UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance.

Authors:  Hazel Tumelo Mufhandu; Kabamba Bankoledi Alexandre; Elin Solomonovna Gray; Lynn Morris; Makobetsa Khati
Journal:  Biochem Biophys Rep       Date:  2016-07-12

5.  Selection and Characterization of ssDNA Aptamers Targeting Largemouth Bass Virus Infected Cells With Antiviral Activities.

Authors:  Qing Yu; Mengmeng Li; Mingzhu Liu; Shuaishuai Huang; Gaoxue Wang; Taixia Wang; Pengfei Li
Journal:  Front Microbiol       Date:  2021-12-17       Impact factor: 5.640

6.  Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?

Authors:  Qian Zhang; Ralf Landgraf
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-18

Review 7.  Aptamers against pathogenic microorganisms.

Authors:  Anna Davydova; Maria Vorobjeva; Dmitrii Pyshnyi; Sidney Altman; Valentin Vlassov; Alya Venyaminova
Journal:  Crit Rev Microbiol       Date:  2015-08-10       Impact factor: 7.624

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.